Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27546759 | 0.90 | GGT1 (0.61) | GGT1FOLH1KMT2AALOX15BLM | |
| SCHEMBL15387334 | 0.90 | GGT1 (0.61) | GGT1FOLH1KMT2AALOX15BLM | |
| SCHEMBL29964294 | 0.88 | FOLH1 (0.53) | GGT1FOLH1ALOX15NOD1CA2 | |
| SCHEMBL29964946 | 0.87 | FOLH1 (0.42) | GGT1FOLH1KMT2AALOX15BLM | |
| SCHEMBL8633803 | 0.86 | GGT1 (0.49) | GGT1FOLH1KMT2AALOX15BLM | |
| SCHEMBL29448584 | 0.86 | MAOA (0.45) | GGT1FOLH1KMT2AALOX15BLM | |
| SCHEMBL30199558 | 0.85 | FOLH1 (0.49) | GGT1FOLH1KMT2AALOX15BLM | |
| SCHEMBL6428434 | 0.83 | FOLH1 (0.47) | GGT1FOLH1KMT2AALOX15BLM | |
| SCHEMBL5495877 | 0.83 | FOLH1 (0.47) | GGT1FOLH1KMT2AALOX15BLM | |
| SCHEMBL6428433 | 0.83 | FOLH1 (0.47) | GGT1FOLH1KMT2AALOX15BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180303944-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATMENT OF MUSCLE WASTING DISEASES | OREGON STATE UNIVERSITY (US) | 2018-10-25 | — | — | US | claimed |
| WO-2018176065-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATMENT OF MUSCLE WASTING DISEASES | OREGON STATE UNIVERSITY (US) | 2018-09-27 | — | — | WO | claimed |
| CN-113616815-B | pH responsive T 1 /T 2 Switching type MRI contrast agent and preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2022-11-22 | — | — | CN | disclosed |
| US-10905766-B2 | Therapeutic compositions and methods for treatment of muscle wasting diseases | OREGON STATE UNIVERSITY (US) | 2021-02-02 | — | — | US | disclosed |
| US-20180303944-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATMENT OF MUSCLE WASTING DISEASES | OREGON STATE UNIVERSITY (US) | 2018-10-25 | — | — | US | disclosed |
| WO-2018176065-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATMENT OF MUSCLE WASTING DISEASES | OREGON STATE UNIVERSITY (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180303944-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATMENT OF MUSCLE WASTING DISEASES | TNNC1, PYGM, MYLK2 | GGT1 2447/4885FOLH1 2135/4885KMT2A 2685/4885 |
| US-10905766-B2 | Therapeutic compositions and methods for treatment of muscle wasting diseases | TNNC1, PYGM, MYLK2 | GGT1 2447/4885FOLH1 2135/4885KMT2A 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.